Cargando…
Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
Silmitasertib (CX-4945) is currently being investigated in clinical trials against various types of cancer. The U.S. Food and Drug Administration (FDA) has already granted orphan drug designation to the compound for the treatment of advanced cholangiocarcinoma, medulloblastoma, and biliary tract can...
Autores principales: | Schwarz, Rico, Richter, Anna, Ito, Elisabeth R. D., Murua Escobar, Hugo, Junghanß, Christian, Hinz, Burkhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028559/ https://www.ncbi.nlm.nih.gov/pubmed/35458589 http://dx.doi.org/10.3390/molecules27082394 |
Ejemplares similares
-
A Simple LC-MS/MS Method for the Quantification of PDA-66 in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022) -
Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020) -
Silmitasertib
(CX-4945), a Clinically Used CK2-Kinase
Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases:
A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023) -
Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012) -
Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)